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Background: Inflammation is a critical component of tumorigenesis, and many cancers arise from sites of
infection, chronic irritation, and inflammation. Inflammatory cytokines triggered by tumors alter hematologic
components, including neutrophil, lymphocyte, and monocyte counts. The neutrophil-to-lymphocyte and
platelet-to-lymphocyte ratios have been shown to be valuable prognostic markers in various types of cancers, including
bladder cancer. Risk stratification based on clinicopathologic data is insufficient to support treatment-related choices in
patients with bladder cancer. Novel prognostic markers are therefore needed. An elevated pretreatment lymphocyte-to-
monocyte ratio (LMR) is reportedly associated with improved overall survival (OS) and a longer time to treatment
recurrence (TTR) in some types of cancers. However, these data are lacking in patients with bladder cancer. The aim of
the present study was to investigate the effect of the preoperative LMR on OS and TTR in a cohort of patients with
bladder cancer.
Methods: Sixty-eight patients with transitional cell carcinoma of the bladder were included in this retrospective analysis.
The associations between a high and low LMR with OS and TTR were analyzed using Kaplan–Meier curves and compared
by the log-rank test.
Results: In our study cohort, an elevated preoperative LMR was significantly associated with an increased TTR (P = 0.001)
and OS (P = 0.020). Patients with an LMR of ≤2.87 showed a median TTR of 2.0 years (95% CI, 0.27–3.73), whereas patients
with an LMR of >2.87 had a median TTR of 11.1 years (95% CI, 2.31–19.88) (P = 0.001). Patients with an LMR of ≤2.81
showed a median OS of 2.7 years (95% CI, 0.63–4.70), whereas patients with an LMR of >2.81 had a median OS of
6.0 years (95% CI, 3.60–8.40) (P = 0.020). The clinical stage at diagnosis was the only clinicopathologic feature associated
with the LMR, while tumor invasion depth showed borderline significance.
Conclusions: The LMR is an easily measured and inexpensive prognostic marker that was significantly correlated with OS
and TTR in the present retrospective analysis. However, because of the small sample size in this study, larger multicenter,
prospective studies are needed.
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Inflammation is a critical component of tumorigenesis, and
many cancers arise from sites of infection, chronic irrita-
tion, and inflammation [1]. It has been hypothesized that
the synthesis of inflammatory cytokines triggered by the
tumor microenvironment alters acute-phase reactants and
hematologic components, including neutrophil, monocyte,
and lymphocyte counts [1,2]. Moreover, nonsteroidal anti-
inflammatory medications have been suggested to reduce
the risk of developing bladder cancer by 19%, implying a
critical correlation between inflammation and bladder can-
cer [3]. The neutrophil-to-lymphocyte and platelet-to-
lymphocyte ratios have been shown to be valuable prog-
nostic markers in patients with various types of tumors
[4-9], including bladder cancer [10,11]. Risk stratification
based on clinicopathologic data is insufficient to support
treatment-related choices in patients with bladder cancer
[12]. Novel prognostic markers that aid in stratifying pa-
tients and making treatment-related decisions are therefore
necessary. However, few data regarding the preoperative
lymphocyte-to-monocyte ratio (LMR) as a prognostic
marker in patients with cancer are currently available. A
low lymphocyte count might result in a weak, insufficient
immunologic reaction to a tumor [13], while an elevated
monocyte count may promote tumorigenesis and angio-
genesis through local immune suppression and stimulation
of tumor neovasculogenesis [14]. Hence, a low LMR may
accurately reflect the presence of a weak immune response
and high tumor burden.
Previous studies of hematologic malignancies suggest
that a survival benefit is associated with an increased
LMR [15,16]. In patients with stage III colon cancer, an
increased LMR might be an independent prognostic
marker of both the time to treatment recurrence (TTR)
and overall survival (OS) [17]. Moreover, a decreased
LMR represents an independent poor prognostic factor
in patients with soft tissue sarcoma [18]. Based on these
findings, we investigated the effect of the preoperative
LMR on OS and TTR in a cohort of patients with blad-
der cancer undergoing cystectomy at our institution.
Methods
We performed a retrospective chart review of patients
diagnosed with bladder cancer at our institution from
1998 to 2007. Approval was obtained from our institu-
tional review board before initiation of the study. The
inclusion criteria were transitional cell carcinoma (TCC)
and the performance of cystectomy. Patients with squa-
mous cell carcinoma, adenocarcinoma, and clear cell
carcinoma and those who did not undergo cystectomy
were excluded from the analysis.
Clinical, histopathologic, and demographic features were
retrospectively obtained from the patients’ medical records.
Staging was performed according to the American JointCommittee on Cancer, 7th edition, 2010. The follow-up
data of all patients were available from routine clinic visits
to their physician. The preoperative white blood cell count
and baseline complete blood cell count were routinely ob-
tained before any interventions. Before neoadjuvant
chemotherapy, the LMR was calculated from this routinely
performed preoperative blood cell count as the absolute
lymphocyte count divided by the absolute monocyte count.
Analysis of the white blood cell count was performed in
the general laboratory of our hospital.
Statistical analysis
Receiver operating characteristic curve analysis was ap-
plied for each OS and TTR event to determine the opti-
mal cut-off levels for the LMR as a predictor of OS and
TTR. OS was defined as the duration of time between
the date of the operation and the date of death of any
cause, and TTR was defined as the duration of time be-
tween the date of the operation and the date of tumor
recurrence. Patients who were still alive or disease-free
were censored at the last follow-up date. Kaplan–Meier
curves were applied to assess the correlation between
the LMR and the time-to-event for OS and TTR. The
log-rank test was used to determine the presence of a
statistical difference in the LMR with respect to survival
or disease progression between the two groups. The me-
dian times to survival and progression and their corre-
sponding standard deviations were retrieved from the
Kaplan–Meier curves. The chi-squared test was per-
formed to identify the relationships between the LMR
and survival and clinical characteristics at the time of
diagnosis. All statistical analyses were performed using the
Statistical Package for Social Sciences, version 20.0 (SPSS
Inc., Chicago, IL, USA). A two-sided P-value of <0.05 was
considered statistically significant in all tests.
Results
The median age of the entire cohort at the time of diagno-
sis was 65 years (range, 43–88 years). The median follow-
up duration was 2 years. Table 1 shows the baseline
patient and tumor characteristics.
Of the 68 patients with TCC bladder cancer, 23 (34%)
developed disease recurrence and 37 (54%) died within
the follow-up period. Receiver operating characteristic
curve analysis showed that the optimal LMR cut-off level
was 2.81 for OS and 2.87 for TTR. The LMR was calcu-
lated for all patients. Tumors recurred in 12 of 30 patients
with an LMR of ≤2.87 and in 11 of 38 patients with an
LMR of >2.87. Seventeen of 29 patients with an LMR
of ≤2.81 and 20 of 39 patients with an LMR of >2.81
died. As shown in Table 2, the clinical stage at diagno-
sis was the only clinicopathologic feature associated
with the LMR, while the tumor invasion depth showed
borderline significance.

















Muscle invasion (4 missing)
Non-muscle invasive 13 20.3
Muscle invasive 51 79.7
Grade at diagnosis
Grade I 9 13.2
Grade II 13 19.1
Grade II 46 67.6
Stage at diagnosis
Stage I 14 20.6
Stage II 22 32.4
Stage III 20 29.4











Parameter Mean ± SD
Hemoglobin (g/dL) 12.3 ± 1.72
WBC count (103/ul) 7.7 ± 1.9
Platelets (103/ul) 263.1 ± 90.7
LN density (among patients
with LN involvement)
37% (Range 12–100)
Table 1 Baseline patient and tumor characteristics
(Continued)
Lymphocyte 24.9 ± 7.9
Range (6–46)
Monocyte 7.0 ± 2.4
Range(2 – 12)
LMR 3.5 ± 1.9
Range (1.38 – 11.50)
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ciated with increased TTR (P = 0.001) (Figure 1).
Patients with an LMR of ≤2.87 showed a median TTR
of 2.0 years (95% CI, 0.27–3.73), whereas patients with
an LMR of >2.87 had a median TTR of 11.1 years (95%
CI, 2.31–19.88) (P = 0.001). Patients with an LMR of ≤2.81
showed a median OS of 2.7 years (95% CI, 0.63–4.70),
whereas patients with an LMR of >2.81 had a median OS
of 6.0 years (95% CI, 3.60–8.40) (P = 0.020) (Figure 2).
Discussion
To the best of our knowledge, this is the first study to
assess the influence of the LMR on OS and TTR in pa-
tients with TCC bladder cancer. Univariate analysisTable 2 Correlation of clinical features with LMR of 2.81
(survival cut-off)
LMR < 2.81 (% ) LMR ≥2.81 (% ) P-value
T Stage




Total 23 (35%) 45 (65%)
Stage at diagnosis




Total 29 (43%) 39 (57%)
Grade at diagnosis
G1 4 5 0.943
G2 5 8
G3 20 26
Total 29 (43%) 39 (57%)
Lymph node density
<0.2 22 34 0.226
≥0.2 7 5
Total 29 (43%) 39 (57%)
Figure 1 Kaplan–Meier Curves: Preoperative LMR of 2.87 and TTR in patients with TCC.
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with a longer TTR, while an LMR of >2.81 was correlated
with better OS. The results of our study are consistent
with those of other studies of various malignancies
[15-18].
Bladder cancer is frequently associated with chronic or
recurrent inflammation, and a high number of inflamma-
tory cells are found at the tumor site [19]. MonocytesFigure 2 Kaplan–Meier Curves: Preoperative LMR of 2.81 and OS in prepresent a source of multiple chemokines/cytokines that
may contribute to inflammation and immune dysfunction
[20]. Monocytes reportedly promote tumorigenesis and
angiogenesis through local immune suppression and
stimulation of tumor neovasculogenesis [14]. Moreover,
macrophages, which are differentiated monocytes, report-
edly support tumor-associated angiogenesis and tumor cell
invasion, migration, and intravasation; they may also leadatients with TCC.
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This could explain why an elevated monocyte count con-
fers a negative prognosis in patients with solid tumors
[23,24].
Lymphocytes, on the other hand, are essential in antitu-
mor reactions of the immune system through induction of
tumor cell apoptosis. They also serve as mediators of
antibody-dependent, cell-mediated cytotoxicity [25,26].
The numbers of T and natural killer cells are reportedly
significantly lower in patients with invasive bladder carcin-
oma than in patients with superficial carcinoma [27].
Moreover, in another study, the CD4/CD8 ratio, lympho-
cyte reactivity to mitogens, and natural killer cell activity
were significantly lower in patients with invasive disease
than in controls and patients with superficial carcinoma
[28]. The same study showed that patients with high-
grade tumors also had a significantly lower CD4/CD8
ratio and lymphocyte activity toward mitogens than did
patients with low-grade tumors [28]. Hence, a low
lymphocyte count might be responsible for a weak, insuf-
ficient immunologic reaction to a tumor and could incur a
negative prognostic outcome [13].
In the present study, the only factor associated with
the LMR was the stage at diagnosis; the tumor depth
showed only borderline significance. The tumor grade
did not have a significant effect on the LMR. Because an
advanced stage at diagnosis has been shown to incur a
negative clinical outcome in the majority of tumors and
was the only feature associated with the LMR in this
study, it is possible that a low LMR reflects an advanced
stage at diagnosis. However, this conclusion needs
further validation in other trials.
The limitations of this study include the small
sample size, which hindered appropriate utilization of
multivariate analysis, and thus the ability to produce
definite conclusions. Moreover, patients were not eval-
uated for active inflammation at the time of the
complete blood cell count; thus, potential confounding
factors such as infection and other disease states such as
ischemia, acute coronary syndrome, diabetes, and renal
and hepatic dysfunction might have affected the lympho-
cyte and monocyte counts.
The LMR constitutes a low-cost predictive biomarker
of the clinical outcome in patients with TCC bladder
cancer and is related to a patient’s adaptive immune
response. Univariate analysis revealed a significant cor-
relation between the TTR and LMR; however, use of the
LMR as an independent prognosticator requires further
evaluation in a large-scale study involving multivariate
analyses.
Conclusions
Invasive bladder cancer remains a challenge to oncolo-
gists and a burden to patients, who exhibit low survivalrates and high tumor recurrence rates. The results of
this study reveal a significant association of the LMR
with both OS and TTR. However, because of the small
number of patients included in this study, our results
need to be properly evaluated in a cohort large enough
to perform valid multivariate analyses.
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